Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a lignan compound

A technology of lignans and compounds, which is applied in the field of application of lignans and can solve problems such as no research reports on lowering blood lipids

Active Publication Date: 2020-07-07
HAINAN MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no research reports on its lipid-lowering

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a lignan compound
  • Application of a lignan compound
  • Application of a lignan compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. Prepare (-)-eugenol-4-O-glucoside from wild pineapple

[0033] Get wild pineapple 5-10kg, decoct with water 3-10 times after pulverizing, each time with 10 times the water of volume decocting 1-6 hour (using the water of 15-50 times of volume altogether). The extracts were combined, filtered, and evaporated to dryness under reduced pressure to obtain extract (about 1000 g). Suspend the extract in 10L distilled water and extract with petroleum ether (5000ml×5-10 times). The mother liquor was extracted with n-butanol to obtain n-butanol extract. The n-butanol extract was taken and loaded onto a silica gel column (Qingdao Ocean Chemical Co., Ltd. column chromatography silica gel, particle size 60-80 μm). Different gradients of chloroform-methanol mixed solvents (chloroform:methanol=100:0-0:100, v / v) were used for elution, and the flow rate was 6-10 ml / min. The amount of mixed solvent for each gradient is 6.0 L, and fractions are collected according to the elu...

Embodiment 2

[0037] Embodiment 2. Characterization of compounds of the present invention

[0038] The structure of the tested compound is determined by its spectral data, and its spectral data are as follows:

[0039] HR-ESI-MS m / z:603.2039[M+Na] + . 1H-NMR (600MHz, DMSO-d 6 )δ:6.66(2H,s,H-2,H-6),6.60(2H,s,H-2',H-6'),4.89(1H,d,J=7.2Hz,H-1” ),4.66(1H,d,J=4.2Hz,H-7'),4.61(1H,d,J=4.2Hz,H-7),4.18(2H,dd,H-9,H-9') ,3.79(2H,m,H-9,H-9'),3.76(6H,s,3,5-OCH 3 ),3.75(6H,s,3',5'-OCH 3 ),3.59(1H,dd,J=11.4,4.2Hz,H-6"),3.40(1H,m,H-6"),3.01~3.20(6H,m,H-2",H-3" ,H-4",H-5",H-8,H-8'); 13 C-NMR (150MHz, Pyr-d 6 )δ: 132.4 (C-1), 105.3 (C-2, C-6), 154.3 (C-3, C-5), 138.7 (C-4), 86.6 (C-7), 55.2 (C- 8), 72.4(C-9), 56.9(2×OCH 3 ), 57.1 (2×OCH 3 ),124.2(C-1'),105.4(C-2',C-6'),149.7(C-3',C-5'),137.7(C-4'),86.69(C-7' ), 55.3(C-8'), 72.6(C-9'), 105.2(glc-1), 776.4(glc-2), 78.7(glc-3), 72.0(glc-4), 79.0(glc- 5), 63.0 (glc-6).

[0040] Based on the spectrum data, it can be determined that the obtained comp...

Embodiment 3

[0041] Embodiment 3. In vivo hypolipidemic effect of the compound of the present invention

[0042] Take 60 golden hamsters of 140-160g, and randomly divide them into blank group, model group, positive drug group, and three dosage groups of compound, namely 40mg·Kg -1 , 20mg·Kg -1 , 10mg·Kg-1 ; Every group of 10, except blank group conventional feed feeding, other groups all feed high-fat feed (2.0% cholesterol, 15% lard, 0.4% bile salt, 82.6% basal feed), and positive drug group gives Simva Statin 5mg·Kg -1 , three dosage groups of compound, high, middle and low were given the compound of the present invention by intragastric administration, and the blank group and the model group were given equal volumes of tap water by intragastric administration. After 40 days of administration, the golden hamsters in each group were fasted for 12 hours, their eyeballs were removed to get blood, centrifuged at 3000r / min for 10 minutes, and the serum was taken, and the content of TC and T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicine, and specifically relates to an application of a lignan compound in the preparation of drugs for reducing blood fat. The disclosed triterpene lignan compound is (-)-syringaresinol-4-O-glucoside, and the structural formula of the lignan compound is represented by the formula (I). The provided compound can prominently inhibit lipid accumulation in-vitro, is capable of obviously reducing the cholesterol and triglyceride in the animal blood of a hyperglycemia model, and has a prominent effect on reducing blood fat. The lignan compound can be used as a novel drug for reducing blood fat, and can be used to treat hyperglycemia, and the drug is user-friendly.

Description

technical field [0001] The invention belongs to the field of biochemical medicine, and in particular relates to the application of a lignan compound. Background technique [0002] Due to abnormal fat metabolism or operation, one or more lipids in plasma are higher than normal, which is called hyperlipidemia. Lipids that are insoluble or slightly soluble in water must be combined with proteins to exist in the form of lipoproteins. Therefore, hyperlipidemia is often hyperlipoproteinemia. Hyperlipidemia is generally manifested as an increase in plasma cholesterol (TC) or triglyceride (TG) levels or both, which can directly cause some diseases that seriously endanger human health, such as atherosclerosis, coronary heart disease, etc. Cardiovascular disease. At present, the use of lipid-lowering drugs is an effective measure for the prevention and treatment of hyperlipidemia. There are many chemical drugs on the market, including statins, fibrates, etc. Although these chemical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P3/06
Inventor 张小坡桂梅张彩云金燕
Owner HAINAN MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com